New Posts New Posts RSS Feed - Veliparib Study For Brca 1 or 2 Metastatic BC
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Veliparib Study For Brca 1 or 2 Metastatic BC

 Post Reply Post Reply
trip2 View Drop Down
Senior Member
Senior Member

Joined: Jun 03 2007
Location: Under Palm Tree
Status: Offline
Points: 8549
Post Options Post Options   Thanks (0) Thanks(0)   Quote trip2 Quote  Post ReplyReply Direct Link To This Post Topic: Veliparib Study For Brca 1 or 2 Metastatic BC
    Posted: Dec 16 2012 at 1:52pm

Study identifier: NCT01506609
Full study details on

Name of PARP Inhibitor used in study:

Veliparib (Abbott)


  • Patients with BRCA1 or BRCA2 mutation
  • Must have confirmed metastatic breast cancer
  • Her2neu negative
    • or Her2neu positive and have received previous anti-Her2neu therapy or are ineligible for anti-Her2neu therapy
  • Subjects must have measurable disease

Exlusion Criteria

  • Patients must be at least 21 days out from prior chemotherapy, radiation therapy, or investigational agent
  • May not have received more than 1 prior line of cytotoxic chemotherapy
  • May not have received prior therapy with with temozolomide, a platinum agent, or a PARP inhibitor
  • May not have received prior taxane therapy for metastatic disease
  • May not have a history of brain or leptomeningeal metastasis
  • See website or contact study team for other exclusion criteria
Stage 2 2003
Stage 1 2007
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.